반응식
[N:1]1[C:10]2[C:5](=[C:6]([NH2:11])[CH:7]=[CH:8][CH:9]=2)[N:4]=[CH:3][CH:2]=1.[N+:12]([C:15]1[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=1[S:21](Cl)(=[O:23])=[O:22])([O-:14])=[O:13].N1C=CC=CC=1>C(Cl)Cl>[N+:12]([C:15]1[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=1[S:21]([NH:11][C:6]1[CH:7]=[CH:8][CH:9]=[C:10]2[C:5]=1[N:4]=[CH:3][CH:2]=[N:1]2)(=[O:23])=[O:22])([O-:14])=[O:13]참가 물질
5
실험 절차
In a similar fashion using route 14 general procedure 26, quinoxalin-5-ylamine (Intermediate 482) (540 mg, 3.7 mmol), 2-nitro-benzenesulfonyl chloride (986 mg, 4.46 mmol), pyridine (0.9 ml, 7.44 mmol) and DCM (10 ml) gave the title compound (679 mg, 56%) after purification by column chromatography with DCM as the eluent.
출처 및 근거
- ORD 기록
- ord-7512a3a30b974f92835ebd98f46493a2
- 출처 데이터셋
- uspto-grants-2015_08
- 특허 번호
- US09102688B2
연결된 노트
불러오는 중…